Soleno Therapeutics (SLNO) Other Operating Expenses (2014 - 2026)

Soleno Therapeutics (SLNO) has 12 years of Other Operating Expenses data on file, last reported at $1.7 million in Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $1.7 million, down 43.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.0 million (up 19.68% YoY), and the FY2025 annual result was $8.2 million, up 154.04% from the prior year.
• Other Operating Expenses eased to $1.7 million in Q1 2026 per SLNO's latest filing, from $1.7 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $3.0 million in Q1 2025 and troughed at -$858000.0 in Q1 2022.
• A 5-year average of $891882.4 and a median of $877000.0 in 2024 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2022 and 2023: Other Operating Expenses tumbled 79.7% in 2022, then jumped 673.48% in 2023.
• A 5-year view of Other Operating Expenses shows it stood at -$602000.0 in 2022, then surged by 279.57% to $1.1 million in 2023, then slumped by 69.75% to $327000.0 in 2024, then surged by 425.08% to $1.7 million in 2025, then declined by 2.04% to $1.7 million in 2026.
• Business Quant data shows SLNO's Other Operating Expenses at $1.7 million in Q1 2026, $1.7 million in Q4 2025, and $1.8 million in Q3 2025.